Navigation Links
Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
Date:2/6/2013

br>(0.42)$
(0.71)Shares used in computing basic and diluted net loss per common share

52,96852,52452,74150,512Selected Balance Sheet Data:December 31, 2012December 31, 2011(Unaudited)Cash, cash equivalents, marketable securities and interest receivable 

$
76,321$
84,463Total assets

82,53387,336Total stockholders' equity

64,89680,132
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, 2015 /PRNewswire/ ... and the life sciences team at Google announced today ... for people with type 1 and type 2 diabetes. ... with Google,s expertise in analytics, miniaturized electronics and low ... improve diabetes care by developing new tools that bring ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Asterias ... focused on the emerging field of regenerative medicine, ... dosed at Chicago -based Rush ... trial evaluating activity of escalating doses of AST-OPC1 ... sensory and motor complete cervical spinal cord injury ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... 15 Omega 3 fatty acids bound to,phospholipids ... natural,alternative and may have beneficial effect on impulsivity ... While several studies have reported,beneficial effects of omega-3 ... have specific positive effects on,impulse control., These ...
... May 14 Biopure Corporation,(Nasdaq: BPUR ... its Phase II coronary,revascularization trial have been ... is entitled "Proof-of-concept trial to,evaluate haemoglobin based ... protocol design, and haemodynamic,results." The manuscript was ...
Cached Medicine Technology:Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement (CDI) ... ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level coding ...
(Date:8/31/2015)... , ... August 31, 2015 , ... Castle Dermatology Institute ... practice. Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. ... his studies at the University of California, Irvine Medical School. As a nationally recognized ...
(Date:8/31/2015)... ... August 31, 2015 , ... “My mother and husband ... inventor, from Hagerhill, Ky. “I thought there could be a comfortable way to prevent ... The Nasal Cannula Ear Protector offers a more secure way to anchor the cannula ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... A year ... the team is preparing to release a new issue commemorating the successful first year. ... information they need for a potentially difficult time in their lives,” says Melissa Wolfert, ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ... the digital healthcare industry. , Consumer driven health plans (CDHPs) are a growing ... advisory and strategic role to the company, and another to answer customers’ questions directly. ...
Breaking Medicine News(10 mins):Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... Mountain View, CA December 5, 2008 ... on developing technologies and products for immune disorders, ... therapeutic treatment for Graft versus Host Disease (GvHD) ... being held December 6 through 9 in San ...
... pseudoephedrine for kids under 2 poses toxicity issues because ... -- Exposure to the decongestant pseudoephedrine, found in many ... among children in the United States. , This is ... the highest risk for toxicity and for whom safe ...
... a USGS study released today,showing that man-made chemicals remained ... the Water Quality Association is encouraging consumers,to educate themselves ... According to a report by the U.S. Geological ... removed by public treatment processes. The,USGS examined water ...
... Launched by Product Stewardship Institute and King Pharmaceuticals ... 5 /PRNewswire-USNewswire/ - - The Product Stewardship ... Dialogue Meeting earlier this week in Washington, DC ... medications to combat increasing rates of prescription drug abuse, ...
... AIDS-causing virus don,t get sick , , FRIDAY, Dec. 5 (HealthDay ... of how a small number of HIV-infected people manage to ... medicine. , The key seems to be an unusual feature ... hope it might lead to better drug therapies or even ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
Cached Medicine News:Health News:Decongestant Exposure Needs Closer Look 2Health News:Chemicals Remain in Most Treated Water, Says Report 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 2Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 3Health News:Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications 4Health News:Special Immune Cells May Be Key to HIV Resistance 2Health News:Secondhand smoke raises odds of fertility problems in women 2
... a two chain (alpha- and beta-subunits) glycoprotein ... the placenta and is normally found in ... the trophoblastic epithelium of the placenta, hCG ... the early stages of pregnancy. The primary ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: